Longeveron (LGVN) Current Deferred Revenue (2021 - 2026)

Longeveron (LGVN) posted quarterly Current Deferred Revenue of $102000.0 for Q1 2026, up 155.0% quarter-over-quarter from $40000.0 in Q4 2025.

Longeveron (LGVN) Current Deferred Revenue (2021 - 2026) Analysis & Trends

Longeveron's Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $102000.0 for Q1 2026.

In Q1 2026, Current Deferred Revenue changed N/A year-over-year to $102000.0; the TTM figure through Mar 2026 stood at $102000.0 (changed N/A YoY), while the FY2025 annual figure was $40000.0, changed 0.0% from the prior year.
Current Deferred Revenue for Q1 2026 stood at $102000.0, up from $40000.0 in the prior quarter.
The five-year high for Current Deferred Revenue was $506000.0 in Q4 2022, with the low at $0.1 in Q2 2024.
The 5-year median for Current Deferred Revenue is $100000.0 (2022), against an average of $128769.2.
The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue slumped 100.0% in 2024, then surged 39999900.0% in 2025.
Longeveron's Current Deferred Revenue stood at $506000.0 in 2022, then changed by 0.0% to $506000.0 in 2023, then sank by 92.09% to $40000.0 in 2024, then changed by 0.0% to $40000.0 in 2025, then soared by 155.0% to $102000.0 in 2026.
Business Quant data shows LGVN's Current Deferred Revenue at $102000.0 in Q1 2026, $40000.0 in Q4 2025, and $40000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Longeveron	26.51 Mn	16.41 Mn	182,000.00

Download Data